A phase 2, randomized, double-blind, placebo-controlled, parallel-group study to assess the safety and efficacy of maraviroc in the treatment of rheumatoid arthritis in subjects receiving methotrexate.

Trial Profile

A phase 2, randomized, double-blind, placebo-controlled, parallel-group study to assess the safety and efficacy of maraviroc in the treatment of rheumatoid arthritis in subjects receiving methotrexate.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 May 2016

At a glance

  • Drugs Maraviroc (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Oct 2009 Results presented at ACR 2009.
    • 29 Sep 2008 Status changed from recruiting to discontinued according to the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top